Development of anti-thrombotic and hypertensive vaccine for prevention of ischemic stroke
暂无分享,去创建一个
[1] C. Anderson,et al. Patterns of Use and Discontinuation of Secondary Prevention Medications After Stroke , 2020, Neurology.
[2] R. Morishita,et al. Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice , 2018, Hypertension.
[3] G. Tsivgoulis,et al. The association of adult vaccination with the risk of cerebrovascular ischemia: A systematic review and meta-analysis , 2018, Journal of the Neurological Sciences.
[4] K. Rundell,et al. Recurrent Ischemic Stroke: Strategies for Prevention. , 2017, American family physician.
[5] R. Morishita,et al. Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress , 2017, Stroke.
[6] R. Morishita,et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction , 2017, Scientific Reports.
[7] M. Filipovic,et al. New antiplatelet drugs and new oral anticoagulants. , 2016, British journal of anaesthesia.
[8] R. Morishita,et al. Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats , 2015, Hypertension.
[9] A. Schmaier,et al. Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. , 2014, The Journal of clinical investigation.
[10] R. Morishita,et al. Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice , 2013, PloS one.
[11] E. Peterson,et al. Secondary preventive medication persistence and adherence 1 year after stroke , 2011, Neurology.
[12] E. Glader,et al. Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke , 2010, Stroke.
[13] H. Volk,et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity , 2007, Journal of hypertension.
[14] N. Hogg,et al. Myeloid Cell Function in MRP-14 (S100A9) Null Mice , 2003, Molecular and Cellular Biology.
[15] T. Auton,et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats , 2000, British journal of pharmacology.
[16] J. Ménard,et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. , 1990, Circulation.
[17] J. Ménard,et al. Active immunization against renin in normotensive marmoset. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[18] O. Cotoi,et al. S 100 A 8 and S 100 A 9 : DAMPs at the Crossroads between Innate Immunity , Traditional Risk Factors , and Cardiovascular Disease , 2017 .
[19] W. Elliott. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study , 2009 .
[20] Morris J. Brown,et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine ( PMD 3117 ) in hypertensive subjects , 2004 .